

Pulmonary Anti-Hypertensives Treatment Selector

Charts reviewed October 2018. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution. For personal use only. Not for distribution.

		ATV/r	DRV/r	LPV/r	EFV	ETV	NVP	RPV	MVC	DTG	RAL	ABC	FTC	3TC	TDF	ZDV	E/C/F/TAF	E/C/F/TDF	
ERA	Ambrisentan	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	
	Bosentan	↑ ^a	↑ ^a	↑ ^a	↓	↓	↓ ^b	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↑ ^a	↑ ^a
	Macitentan	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
PDE5	Sildenafil	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
	Tadalafil	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
sCG	Riociguat	↑	↑	↑	↓	↓	↓	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↑	↑
PA	Epoprostenol	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Iloprost	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
	Treprostinil	↑	↑	↑	↑	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔
IPr	Selexipag	↔ ^c	↔ ^c	↔ ^c	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔	↔ ^c	↔ ^c

Colour Legend

- No clinically significant interaction expected.
- These drugs should not be coadministered.
- Potential interaction which may require a dosage adjustment or close monitoring.
- Potential interaction predicted to be of weak intensity. No *a priori* dosage adjustment is recommended.

Text Legend

- ↑ Potential increased exposure of the pulmonary antihypertensive
- ↓ Potential decreased exposure of the pulmonary antihypertensive ↓↓ Potential decreased exposure of HIV drug
- ↔ No significant effect

- ERA Endothelin receptor antagonist
- PDE5 Phosphodiesterase 5 inhibitors
- sCG Soluble guanylate cyclase stimulators
- PA Prostacyclin analogues
- IPr IP receptor agonists

- a When starting bosentan in individuals already on ritonavir or cobicistat containing regimens use a bosentan dose of 62.5 mg once daily or every other day. Discontinue bosentan at least 36 h prior to starting a ritonavir or cobicistat containing regimen and restart after at least 10 days at 62.5 mg once daily or every other day.
- b Potential additive liver toxicity.
- c Exposure of selexipag increased, but exposure of active metabolite unchanged.